Form 4: Corcept Therapeutics Director Kimberly Park Granted 15,000 Stock Options

Corcept Therapeutics Inc. director Kimberly Park was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Summary

• Kimberly Park, a Director of Corcept Therapeutics Inc. (CORT), was granted 15,000 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $72.27.
• The options will become exercisable ratably in equal installments on each monthly anniversary of June 10, 2025, over a one-year period.
• Vesting is subject to Ms. Park's continued service on each monthly vesting date.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Kimberly Park directly beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for the individual, aligning their incentives with the company's performance. For the company, it represents a standard compensation practice to attract and retain talent, which is generally viewed as a neutral to slightly positive operational event.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value creation of Corcept Therapeutics.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• No immediate negative implications are apparent from this routine equity grant.

Risks

• The value of the stock options is subject to the future market price of Corcept Therapeutics' common stock; if the stock price does not exceed the exercise price, the options may expire worthless.
• The options are subject to forfeiture if the reporting person's service to the company ceases before the vesting period is complete.

Future Outlook

This Form 4 filing pertains to an insider equity grant and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term incentives are crucial for aligning leadership interests with innovation and growth strategies.

Comparison to Industry Standards

• The structure of this equity grant, involving stock options with a multi-year vesting schedule, is consistent with typical director compensation packages observed in the pharmaceutical and biotechnology industries.
• While specific comparable companies or projects are not detailed in this filing, similar equity grants are routinely disclosed by peers such as Neurocrine Biosciences (NBIX) or Sage Therapeutics (SAGE) for their non-employee directors, aiming to incentivize long-term commitment and performance.

Related Party Transactions

• The grant of 15,000 stock options to Kimberly Park, a director of Corcept Therapeutics Inc., constitutes a transaction with a related party as part of her compensation for board service.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Kimberly Park): Receives equity compensation, aligning her financial interests with the company's long-term success.

Next Steps

• Kimberly Park's continued service to Corcept Therapeutics Inc. is required for the options to vest monthly over the one-year period.
• Upon vesting, Ms. Park will have the right to exercise the options at the specified price of $72.27 per share until the expiration date of June 10, 2035.

Key Dates

Keywords

Corcept Therapeutics, CORT, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Kimberly Park, SEC Filing